Uterine Cancer Study Act of 2025 | ChamberLight

IN COMMITTEE· 119TH CONGRESS

House BillHR 4396Health

Uterine Cancer Study Act of 2025

INTRO JUL 15· LAST ACTION JUL 15

READING

3MIN

COSPONSORS

READER REACTIONS0 TOTAL

NO VOTES YET · BE THE FIRST

Introduced only

LEGISLATIVE PROGRESS

STEP 2 / 8

Introduced

In Committee

Reported

Passed House

Passed Senate

Conference

To President

Became Law

WHAT THE BILL DOES

AI-written

This bill addresses a growing public health concern regarding the potential link between common beauty products and serious health issues like cancer. Recent scientific studies have suggested a connection between chemical hair straighteners and uterine cancer, with women of color experiencing higher rates of both use and diagnosis. If this bill passes, it would fund a comprehensive government-backed investigation to provide definitive answers.

Voters should care because it could provide crucial information for millions of people about the safety of products they use. If a clear link is established, it could lead to better-informed choices for consumers, improved product safety standards, and potentially reduce cancer risks. Without this bill, the government might not conduct such a focused and extensive study, leaving consumers without critical information about potential health hazards from products widely available on the market.

KEY PROVISIONS

5AI-extracted

PROVISION 01

Directs the Secretary of Health and Human Services (HHS) to conduct a study on the link between chemical hair straighteners and uterine cancer.

This initiates a formal government investigation into a potential public health risk.

PROVISION 02

Requires the study to specifically focus on the increased incidence of uterine cancer among women of color.

This addresses health disparities and ensures the study prioritizes a disproportionately affected demographic.

PROVISION 03

Mandates that the study consider whether the Food and Drug Administration (FDA) should impose additional safety testing requirements on hair straightener manufacturers.

This provision could lead to stronger consumer protection and product safety regulations.

PROVISION 04

Requires the study to review existing research and separate results based on the presence of dyes, bleach, highlights, or perms in hair straighteners.

This ensures a comprehensive review and a detailed understanding of potential varying risks associated with different product types.

PROVISION 05

Sets specific deadlines for submitting the study methodology, commencing the study, and delivering the final report to Congress.

These deadlines ensure accountability and a timely progression of the research.

SPONSORSHIP

1 + 38

COSPONSOR BREAKDOWNBIPARTISAN · 0%

DEM 38 REP 0 IND 0

ACTION TIMELINE

2 EVENTS

JUL 15

Introduced in House

INTROREFERRAL

JUL 15

Referred to the House Committee on Energy and Commerce.

HOUSE · INTROREFERRAL

BILL INFO

TypeHouse Bill

NumberHR 4396

Congress119th

StatusIn Committee

IntroducedJul 15, 2025

Last actionJul 15, 2025

READER REACTIONS

OVERALL SENTIMENT

No reactions yet. Be the first to weigh in.

Discussion

Loading comments...

Call my reps

IN COMMITTEE· 119TH CONGRESS · ENERGY AND COMMERCE COMMITTEE · INTRODUCED JUL 15, 2025

House BillHR 4396Health

Uterine Cancer Study Act of 2025

INTRODUCED JUL 15, 2025· LAST ACTION JUL 15, 2025

PASSAGE CHANCES

—%

READING

3 min

COSPONSORS

COMPLEXITY

Moderate

Call my reps Congress.gov

LEGISLATIVE PROGRESS

STEP 2 OF 8

Introduced

In Committee

Reported

Passed House

Passed Senate

Conference

To President

Became Law

Introduced
In Committee
Reported
Passed House
Passed Senate
Conference
To President
Became Law

WHAT THE BILL DOES

AI-written

KEY PROVISIONS

AI-extracted

high

Directs the Secretary of Health and Human Services (HHS) to conduct a study on the link between chemical hair straighteners and uterine cancer.

This initiates a formal government investigation into a potential public health risk.

high

Requires the study to specifically focus on the increased incidence of uterine cancer among women of color.

This addresses health disparities and ensures the study prioritizes a disproportionately affected demographic.

high

Mandates that the study consider whether the Food and Drug Administration (FDA) should impose additional safety testing requirements on hair straightener manufacturers.

This provision could lead to stronger consumer protection and product safety regulations.

med

Requires the study to review existing research and separate results based on the presence of dyes, bleach, highlights, or perms in hair straighteners.

This ensures a comprehensive review and a detailed understanding of potential varying risks associated with different product types.

med

Sets specific deadlines for submitting the study methodology, commencing the study, and delivering the final report to Congress.

These deadlines ensure accountability and a timely progression of the research.

DEADLINES & DATES

AI-extracted

An AI model extracted this from the bill’s official record and can make mistakes. Check the official text ↗ (opens in new tab)

Not later than 45 days after the date of enactment of this Act.

Secretary must submit a description of the study methodology.

Not later than 180 days after the date of enactment of this Act.

Secretary must commence the study.

Not later than 2 years after the date of enactment of this Act.

Secretary must complete the study and submit a report on the results to Congress.

GLOSSARY

AI-written

Secretary of Health and Human Services: The head of the U.S. government department responsible for health and social services programs.
Uterine Cancer: A type of cancer that begins in the uterus, the hollow, pear-shaped organ where a baby grows during pregnancy.
Hair straighteners: Chemical products used to make curly or wavy hair straight.
Commissioner of Food and Drugs: The chief official of the Food and Drug Administration (FDA), the agency responsible for protecting public health by ensuring the safety and effectiveness of products like medications and cosmetics.
Director of the National Institutes of Health: The leader of the National Institutes of Health (NIH), the primary U.S. government agency for medical research.
Enactment: The process of a bill becoming a law after being passed by both houses of Congress and signed by the President.
Disaggregate: To separate something into its individual parts or components for analysis.

ACTION TIMELINE

2 EVENTS

JUL 15, 25

Introduced in House

INTROREFERRAL

JUL 15, 25

Referred to the House Committee on Energy and Commerce.

INTROREFERRAL

READER REACTIONS

0 COMMENTS

WHAT DO YOU THINK?

What do you think?

0 votes

Discussion

Loading comments...

MORE INFORMATION

Committee Referrals

Energy and Commerce CommitteeReferred

Jul 15, 2025

house

Search

Uterine Cancer Study Act of 2025

LEGISLATIVE PROGRESS

WHAT THE BILL DOES

KEY PROVISIONS

SPONSORSHIP

ACTION TIMELINE

BILL INFO

READER REACTIONS

Discussion

Uterine Cancer Study Act of 2025

LEGISLATIVE PROGRESS

WHAT THE BILL DOES

KEY PROVISIONS

DEADLINES & DATES

GLOSSARY

ACTION TIMELINE

SPONSORS

READER REACTIONS

What do you think?

Discussion

MORE INFORMATION

Committee Referrals

Related Legislation